



Published in final edited form as:

IJC Metab Endocr. ; 4: 28–32. doi:10.1016/j.ijcme.2014.07.004.

Endothelial Dysfunction is Associated with Occult Coronary Artery Disease Detected by Positron Emission Tomography

Ambar Kulshreshtha, MD, MPH^{a,b}, Yan Zheng, MD, MPH^a, Arshed A. Quyyumi, MD^b, Emir Veleidar, PhD^{a,b}, John Votaw, PhD^c, Irina Uphoff^c, Douglas J. Bremner, MD^d, Jack Goldberg, PhD^{e,f}, and Viola Vaccarino, MD, PhD^{a,b}

^a Department of Epidemiology, Emory University School of Public Health, Atlanta, GA

^b Division of Cardiology, Emory University School of Medicine, Atlanta, GA

^c Department of Radiology, Emory University School of Medicine, Atlanta, GA

^d Department of Psychiatry, Emory University School of Medicine, Atlanta, GA

^e Vietnam Era Twin Registry, Seattle, WA

^f University of Washington School of Public Health, Seattle, WA

Abstract

Objective—Silent myocardial ischemia is common in asymptomatic subjects without a prior history of coronary artery disease (CAD) and is associated with increased morbidity and mortality. Our objective was to determine whether endothelial dysfunction is associated with silent myocardial ischemia and whether the association is independent of genetic and familial factors.

Material and methods—We examined 416 male monozygotic and dizygotic twins aged 47 to 63 years, free of symptomatic CAD. Subclinical ischemia was diagnosed by [¹³N] ammonia positron emission tomography at rest and after adenosine stress. Endothelial function was measured by flow-mediated dilation (FMD) of the brachial artery. Generalized estimating equations were used for analysis.

Results—Fixed perfusion defects were found in 24 (6%) twins and reversible perfusion defects in 90 (22%) twins, indicating subclinical ischemia. There was an inverse correlation between FMD and the reversible perfusion defect score ($r = -0.14$, $p=0.01$) but not the fixed defect score ($r = -0.017$, $p=0.73$). From the lowest to the highest quartile of FMD, the prevalence of reversible defects decreased 28% to 14%, $p=0.008$. In multivariable analysis, reversible defects were significantly associated with each quartile of decreasing FMD (OR =1.3; 95% 1.1, 2.5). In 54 twin

© 2014 The Authors. Published by Elsevier B.V.

Corresponding Author: Viola Vaccarino, MD, PhD Professor and Chair, Dept. of Epidemiology Professor, Dept. of Medicine, School of Medicine 1518 Clifton Rd NE, Room 3011, RSPH, Emory University Atlanta, GA 30322 Phone: 404-727-8710 Fax: 404-727-8737 viola.vaccarino@emory.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures: None

pairs discordant for endothelial dysfunction (FMD 7% dilation from baseline), twins with endothelial dysfunction had 9% higher likelihood of having perfusion defects than their co-twins without endothelial dysfunction (p=0.041).

Conclusions—Endothelial dysfunction is independently associated with silent ischemia and this association is not confounded by genetic or other shared familial factors.

Keywords

Endothelial dysfunction; Silent ischemia; Flow-mediated vasodilation; Positron Emission Tomography

1. INTRODUCTION

Normal vascular endothelium, by secreting several mediators including nitric oxide, promotes arterial vasodilation, prevents thrombosis, and has anti-proliferative and anti-inflammatory actions. Dysfunction of the endothelium is characterized by impaired vasodilation in response to endothelial-specific agonists that reflects abnormalities in the integrity and function of the vascular endothelium.[1,2] This dysfunction plays a critical role in the pathogenesis of atherosclerotic coronary artery disease (CAD) and often precedes development of structural atherosclerosis.[3-7] Endothelial dysfunction can be measured by intra-arterial infusion of agonists that promote release of nitric oxide, such as acetylcholine, but these techniques are invasive and are thus have limited applicability.[8] Flow-mediated dilation (FMD) of the brachial artery is an ultrasound-based method that allows non-invasive assessment of vascular nitric oxide release in response to increased shear stress.[9] FMD correlates with traditional vascular risk factors and is an independent measure of long term outcomes in both patients with CAD and in the general population. [10-18]

Based on myocardial perfusion imaging, asymptomatic subjects frequently (20-50%) have perfusion abnormalities suggestive of silent ischemia.[19] These perfusion abnormalities may be due to either hemodynamically significant coronary stenosis, or occur in the absence of significantly obstructive CAD, and in this case have been attributed to coronary microvascular endothelial dysfunction.[20] However, the relationship between silent myocardial ischemia and peripheral vascular endothelial dysfunction remains unknown. Such an association may provide mechanistic explanation for the worse long term prognosis in subjects with endothelial dysfunction, and potentially provide a way to identify a high risk group within an asymptomatic population. In this study, we investigated the relationship between peripheral vascular endothelial dysfunction and silent myocardial ischemia in asymptomatic middle-aged, male twins without a prior history of CAD, with the hypothesis that endothelial dysfunction, measured as FMD, will identify a population at risk of silent myocardial ischemia diagnosed by positron emission tomography (PET). Twin studies provide a unique opportunity to examine the association between risk factors and disease because twins are matched on shared early environment and genetic factors, since twin siblings share genes (50% on average if dizygotic (DZ) and 100% if monozygotic (MZ)), maternal, and early familial environmental factors.[21]

2. MATERIAL AND METHODS

2.1 Study population

The Emory Twin Studies includes samples recruited in two companion studies: the Twins Heart Study (THS) and the Stress and Vascular Evaluation in Twins (SAVEIT). The purpose of these studies was to elucidate the role of psychological, behavioral, and biologic risk factors for subclinical cardiovascular disease in twins. Both studies recruited randomly selected samples of middle-aged male MZ and DZ twin pairs (who were raised in the same household) from the Vietnam Era Twin (VET) Registry, which includes 7369 male-male twin pairs both of whom served in the US military during the time of the Vietnam War. [22] Both studies followed identical procedures, measurements, and protocols. THS enrolled 180 twin pairs between 2002 and 2006 and SAVEIT included 127 twin pairs enrolled between 2005 and 2010 as previously described. [20, 23, 24] After excluding the second visit of a few pairs who participated in both studies, the combined sample included 281 pairs. Pairs of twins were examined at the same time at the Emory University General Clinical Research Center, and all data collection, occurred during a 24-hour admission under controlled conditions. Both studies were approved by the Emory Institutional Review Board, and all twins signed an informed consent. Zygosity information by means of DNA typing was available for all twin pairs.

2.2 Cardiovascular Risk Assessment

A medical history and a physical examination were obtained on all twins. Systolic and diastolic blood pressure was measured by mercury sphygmomanometer on the right arm with the subject in sitting position after 10 minutes of rest. The average of two measurements 5 minutes apart was used in the statistical analyses. Venous blood samples were drawn for the measurement of glucose and lipid profile after an overnight fast. Direct low-density lipoprotein (LDL) cholesterol was obtained using homogeneous assays (Equal Diagnostics, Exton, Pennsylvania). Cigarette smoking was classified into current smoker (any number of cigarettes) versus never or past smoker. Diabetes mellitus was defined as having a fasting glucose level of >126 mg/dl or being treated with anti-diabetic medications.

2.3 Flow-mediated Dilation (FMD)

Endothelium-dependent brachial artery FMD was determined using bi-mode ultrasound according to standardized procedures as described previously.[25,26] Images were obtained with an Acuson 10-mHz linear array transducer and ultrasound system (Mountain View, CA, USA). We performed imaging with the subject resting supine for at least 10 min on a hospital bed in a quiet setting. Optimal brachial artery images were obtained between 2 and 10 cm above the antecubital crease. After baseline measurements, a blood pressure cuff was inflated to 200 mmHg over the proximal portion of the right forearm for 5 min. Endothelium-dependent function was determined during the first 2 min of release of the cuff. [27] After a 15-min period to re-establish baseline conditions, endothelium-independent dilation was assessed with similar procedures before and 3 min after administration of 0.4 mg of sublingual nitroglycerin. Images were digitized online, and arterial diameters were measured with edge-detection software (Medical Imaging Applications, Coralville, IA, USA) by an individual blinded to subject data. Arterial

diameter was measured in millimeters from the leading edge of the intima–lumen interface of the near wall (echo zone 3) to the leading edge of the lumen–intima interface of the far wall (echo zone 5), coincident with the R-wave on the electrocardiogram (i.e. end-diastole). The brachial artery vasodilator response was quantified as percentage change in vessel diameter from baseline. In our laboratory, the mean difference in FMD (%) between two consecutive assessments performed in 11 subjects an average of 8 days apart was 1.26% ($\pm 0.76\%$), with a Pearson's correlation of 0.75. The mean difference in the FMD (%) between two readings of the same 11 measurements was 0.82% ($\pm 0.48\%$), with a Pearson's correlation of 0.97.

2.4 Myocardial Perfusion

Twins underwent imaging of myocardial blood flow with PET [^{13}N] ammonia at rest and following pharmacologic (adenosine) stress. On the day prior to the PET scan, they abstained from smoking and drinking alcoholic or caffeinated beverages. All medications were held the morning of the PET scan.

Initially, a 2-3 mCi dose of [^{13}N] ammonia was injected and a 4-minute static scan was collected and reconstructed without any corrections to verify subject position. Then, rest and pharmacological stress (adenosine) ammonia imaging was performed on each subject. The rest and stress imaging protocols were identical except that a 4-minute infusion of adenosine (0.14 mg/Kg/min) was started 2 minutes prior to the ammonia injection for the stress imaging session. 20 mCi of [^{13}N] ammonia were injected and a 5-minute, 31 frame dynamic acquisition was started (12 frames \times 5 sec, 3 frames \times 20 sec, 1 frame \times 300 sec). Data were collected in 47 planes 3.375 mm thick covering a range of 16 cm for the CTI ECAT 921 camera or in 35 planes, 4.25 mm thick, covering a range of 15 cm for the GE PET-CT Discovery LS scanner. Immediately after the conclusion of the dynamic sequence, a 15-min gated (8 equally spaced phased gates) acquisition was started. The injections of ammonia were separated by at least 50 minutes to allow [^{13}N] ammonia from the first injection to decay to a level where it would not interfere with the second study. Images were reconstructed with filtered back projection using a Hann filter cutoff at 1 cycle/cm and included attenuation correction.

We constructed a summary score describing the number and the severity of visible perfusion defects across 20 myocardial segments. In each segment, the defect severity was quantified on a 4-point scale (0: normal; 4: absent perfusion) and subsequently summed across the 20 segments to yield a total score. Separate scores were obtained for the rest (summed rest score) and stress (summed stress score) scans. The difference between these scores, the summed difference score, was computed to provide an overall indication of reversible ischemia. In addition we computed dichotomous indicators of perfusion abnormalities, defined as a summed stress score ≥ 4 across all 20 segments. [28]

2.5 Statistical analysis

Continuous variables were described as mean \pm SD and categorical variables as frequencies (percent). We compared baseline demographic characteristics, cardiovascular risk factors, and perfusion defect scores (both reversible and fixed) across quartiles of FMD treating the

twins as individuals, while accounting for correlated data using mixed models or generalized estimating equation (GEE) models. In additional analyses, we examined the Spearman correlation between perfusion scores and FMD both treated as continuous variables. Next, we analyzed the relationship between FMD and perfusion defects using mixed model linear regression analysis adapted for twin studies. [29] We treated perfusion defects as an outcome for these models using dichotomous categorization (normal or abnormal based on a score ≥ 4). We then adjusted for cardiovascular risk factors that include age, body mass index (BMI), high, total, and low density lipoprotein cholesterol, current smoking, systolic blood pressure, fasting plasma glucose and history of major depression. In a separate model we accounted for cardiovascular risk factors, use of aspirin and statins, as well as anti-hypertensive medications, including beta blockers, ace-inhibitors, diuretics, and angiotensin receptor blockers. Potential multicollinearity was investigated using condition indexes and variance decomposition proportions by means of a SAS macro including both a condition index of > 20 and at least 2 non-intercept variables with variable decomposition proportions values of >0.05 .

We next analyzed twin pairs discordant for endothelial dysfunction where one member had endothelial dysfunction and their twin brother did not. The highest quartile of hyperemia dilation ($>7\%$) compared to lower quartiles was used to categorize endothelial dysfunction as normal vs abnormal. This within-pair analysis automatically takes into account shared familial and many early environmental factors. Within-pair analysis was further stratified by zygosity to determine whether the relationship between reversible defects and FMD was different between monozygotic and dizygotic twins. The analysis of within-pair differences in monozygotic twins is fully controlled for genetic factors shared between FMD and myocardial ischemia. Dizygotic twins share on average 50% of genes and differences among the twins are only partially controlled for shared genetic factors. Shared genetic factors would be indicated if the within-pair difference in reversible defects in endothelial dysfunction -discordant pairs is smaller in monozygotic than in dizygotic pairs. All statistical analyses were conducted using SAS software, version 9.2 (SAS Institute Inc, NC). Significance level was set at 0.05, two- sided.

3. RESULTS

From the initial sample of 281 twin pairs (562 subjects), we excluded 65 twins because of previous history of CAD. Furthermore, 81 twins were excluded because of missing data on PET or FMD due to scheduling conflicts or technical problems with the imaging equipment or processing. The final sample of 416 twins (mean age 55 years, range 47 to 63 years) was 94% white and 3% black, 64% MZ and 36% DZ, a distribution that is similar to the Vietnam Era Twin Registry. There were no significant differences in demographic variables between MZ and DZ twins. Twins in the higher FMD quartiles had lower systolic blood pressure and alcohol consumption; no other significant differences were noted (Table 1).

Fixed perfusion defects were observed in 24 (6%), and reversible perfusion defects in 90 (22%) twins. The summed stress score, but not the rest score, tended to be lower in twins with higher FMD, and the summed difference score was negatively correlated with FMD quartiles (Table 2). When stress perfusion was dichotomized as normal or abnormal based

on a score ≥ 4 , twins in the highest quartile of FMD had lower prevalence of stress defects compared with twins in the lower FMD quartiles. Thus, from the lowest to the highest quartile of FMD, the prevalence of reversible defects decreased from 28% to 14% (p for trend=0.008). In contrast, there was little difference in fixed defects based on endothelial function. Similarly, when FMD was treated as a continuous variable, it was negatively correlated with the reversible perfusion defect score (Spearman $r = -0.14$, $p=0.01$.) but not the fixed defect score (Spearman $r = -0.017$, $p=0.73$).

In the unadjusted model, subjects in the lowest FMD quartile exhibited twice the odds of myocardial ischemia (presence of reversible perfusion defects) (OR=2.0, 95% CI 1.6-2.7) compared with the highest quartile (Table 3) This association was only mildly diminished after adjusting for age, smoking, BMI, systolic blood pressure, plasma lipids and fasting glucose. There was no association between FMD and fixed defects.

Our final analyses focused on twin pairs who were discordant for endothelial dysfunction (defined as FMD $\geq 7\%$ dilation from baseline diameter), i.e. where one member had endothelial dysfunction and his twin brother did not. In 54 discordant twin pairs, twins with endothelial dysfunction had 9% higher likelihood to have perfusion defects than their co-twins without endothelial dysfunction ($p=.041$). Results for MZ and DZ twin pairs were similar.

4. DISCUSSION

In asymptomatic subjects without a prior history of CAD, endothelial dysfunction, as demonstrated by reduced FMD, is independently associated with inducible myocardial ischemia. This relationship remained significant even after adjustment for traditional CAD risk factors. These findings were confirmed in twin pairs discordant for endothelial dysfunction, where those with endothelial dysfunction were more likely to have reversible perfusion defects than their co-twins (both monozygotic and dizygotic) without endothelial dysfunction. Therefore, it appears that the relationship between FMD and myocardial ischemia is not confounded by CVD risk factors, shared genetic or other familial factors. Thus, in asymptomatic individuals without a history of CAD, endothelial dysfunction is associated with a higher risk of reversible myocardial ischemia. Our results suggest that endothelial dysfunction may be implicated in asymptomatic myocardial ischemia.

Endothelial function is an excellent barometer of vascular health.[2,30] Abnormal endothelial function is associated with greater risk factor burden and coronary atherosclerosis, and improves in response to anti-atherosclerotic therapies.[31-33] Coronary endothelial dysfunction correlates with peripheral endothelial dysfunction and both are markers of subsequent increased risk of adverse cardiovascular events in patients with and without established CAD.[14,16,34] Although, prior studies in CAD patients have linked endothelial dysfunction to myocardial perfusion defects,[35] no previous studies have examined if this is also true in asymptomatic individuals without prior history of CAD among whom the etiology of perfusion abnormalities is not known.[36-38] In our study of asymptomatic, community individuals without a clinical history of CAD, a lower FMD was

associated with a doubling in risk of silent myocardial ischemia, suggesting that endothelial dysfunction is an important underlying mechanism.

Silent ischemia, defined as myocardial ischemia occurring in the absence of angina or angina equivalents, is a common yet frequently unrecognized manifestation of CAD, accounting for more than 75% of ischemic episodes during daily life.[39,40] Silent ischemia is an independent predictor of future cardiac events even in patients without a history of CAD, whether it is detected by exercise testing, ambulatory electrocardiography, or imaging modalities.[41,42] Importantly, up to 48% of subjects with known CAD and silent ischemia detected by electrocardiography have an adverse cardiac event within 4 to 6 years.[43,44] Whether community screening with FMD is of benefit in reducing the risk of coronary events and cardiac death, however, needs to be further evaluated.

Despite being asymptomatic and without a clinical history of CAD, 22% of our sample had reversible perfusion defects on cardiac PET perfusion imaging. Consistent with our data, the prevalence of myocardial perfusion abnormalities in asymptomatic subjects has been reported to be between 20-50% and is attributed to the presence of CAD risk factors and/or family history.[19,45,46] A number of underlying mechanisms have been suggested for ischemia being silent, including subclinical epicardial disease, microvascular dysfunction, [47] blunted pain perception or insufficient degree of ischemia to stimulate pain receptors. Our findings suggest that endothelial dysfunction can play an important pathophysiologic role, independent of traditional CAD risk factors and family background and provides mechanistic insight for the link between FMD and coronary heart disease events. [14] [34,48,49].

Our study has several strengths. We have the advantage of a relatively large sample size and a twin study design. Twins provide naturally matched pairs where the potential confounding effects of a large number of factors such as sociodemographic, genetic and other familial influences are removed by comparisons within twin pairs. Our study also had the advantage of detailed measures of CVD risk factors and lifestyle behaviors. There are also a few limitations. Our analyses are cross-sectional and thus we are unable to address the temporal relationship between FMD and silent ischemia. Further, the sample is restricted to predominantly healthy middle-aged male Vietnam era veterans, and therefore, our results may not be generalizable to women and may not extend to younger subjects or populations with clinically manifest cardiovascular disease. Also we have no coronary angiography data on these participants to confirm or exclude the presence of obstructive CAD.

In conclusion, we showed that endothelial dysfunction, as assessed by means of brachial artery FMD, is independently associated with a 2-fold increased risk of silent ischemia in predominantly healthy asymptomatic men, independent of CVD risk factors, and shared genetic or environmental factors. Our results support growing evidence linking endothelial dysfunction to the early phases of CAD and point to a key role of the endothelium in the pathophysiology of myocardial ischemia.

Acknowledgments

This study was supported by K24HL077506, R01 HL68630 and R01 AG026255 to VV, and by K24 MH076955 to JDB from the National Institutes of Health; by the Emory University General Clinical Research Center MO1-RR00039 and by grant 0245115N from the American Heart Association. The United States Department of Veterans Affairs has provided financial support for the development and maintenance of the Vietnam Era Twin (VET) Registry. Numerous organizations have provided invaluable assistance, including: VA Cooperative Study Program; Department of Defense; National Personnel Records Center, National Archives and Records Administration; the Internal Revenue Service; National Opinion Research Center; National Research Council, National Academy of Sciences; and the Institute for Survey Research, Temple University.

Abbreviations List

CAD	Coronary Artery Disease
FMD	Flow-mediated Dilation
PET	Positron Emission Tomography

References

1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res.* 2000; 87:840–844. [PubMed: 11073878]
2. Quyyumi AA. Prognostic value of endothelial function. *Am J Cardiol.* 2003; 91:19H–24H.
3. Zeiher AM, Drexler H, Wollschlaeger H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. *Circulation.* 1991; 83:391–401. [PubMed: 1991363]
4. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr. et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. *N Engl J Med.* 1991; 325:1551–1556. [PubMed: 1944439]
5. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. *N Engl J Med.* 1995; 332:512–521. [PubMed: 7830734]
6. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. *J Am Coll Cardiol.* 1994; 23:833–843. [PubMed: 8106687]
7. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? *J Am Coll Cardiol.* 1997; 30:325–333. [PubMed: 9247501]
8. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. *Circulation.* 1995; 91:1314–1319. [PubMed: 7867167]
9. Mitchell GF, Parise H, Vita JA, Larson MG, Warner E, et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. *Hypertension.* 2004; 44:134–139. [PubMed: 15249547]
10. Patel S, Celermajer DS. Assessment of vascular disease using arterial flow mediated dilatation. *Pharmacol Rep.* 2006; 58(Suppl):3–7. [PubMed: 17332665]
11. Li J, Zhao SP, Li XP, Zhuo QC, Gao M, et al. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. *Int J Cardiol.* 1997; 61:165–169. [PubMed: 9314210]
12. Kirma C, Akcakoyun M, Esen AM, Barutcu I, Karakaya O, et al. Relationship between endothelial function and coronary risk factors in patients with stable coronary artery disease. *Circ J.* 2007; 71:698–702. [PubMed: 17456994]
13. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. *J Am Coll Cardiol.* 1994; 24:1468–1474. [PubMed: 7930277]

14. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation*. 2000; 101:1899–1906. [PubMed: 10779454]
15. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the “vulnerable” patient. *Circulation*. 2004; 110:1926–1932. [PubMed: 15451794]
16. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr. et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation*. 2000; 101:948–954. [PubMed: 10704159]
17. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, et al. Prognostic value of coronary vascular endothelial dysfunction. *Circulation*. 2002; 106:653–658. [PubMed: 12163423]
18. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. *Circulation*. 2001; 104:191–196. [PubMed: 11447085]
19. Sdringola S, Patel D, Gould KL. High prevalence of myocardial perfusion abnormalities on positron emission tomography in asymptomatic persons with a parent or sibling with coronary artery disease. *Circulation*. 2001; 103:496–501. [PubMed: 11157712]
20. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. *Arch Intern Med*. 2009; 169:843–850. [PubMed: 19433695]
21. Burbridge D. Francis Galton on twins, heredity and social class. *Br J Hist Sci*. 2001; 34:323–340. [PubMed: 11700679]
22. Goldberg J, Curran B, Vitek ME, Henderson WG, Boyko EJ. The Vietnam Era Twin Registry. *Twin Res*. 2002; 5:476–481. [PubMed: 12537880]
23. Zhao J, Cheema FA, Reddy U, Bremner JD, Su S, et al. Heritability of flow-mediated dilation: a twin study. *J Thromb Haemost*. 2007; 5:2386–2392. [PubMed: 17848176]
24. Vaccarino V, Khan D, Votaw J, Faber T, Veledar E, et al. Inflammation is related to coronary flow reserve detected by positron emission tomography in asymptomatic male twins. *J Am Coll Cardiol*. 2011; 57:1271–1279. [PubMed: 21392641]
25. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol*. 2002; 39:257–265. [PubMed: 11788217]
26. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. *J Am Coll Cardiol*. 2011; 58:186–192. [PubMed: 21718915]
27. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med*. 2003; 348:593–600. [PubMed: 12584367]
28. Hachamovitch R, Berman DS, Kiat H, Cohen I, Cabico JA, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease : incremental prognostic value and use in risk stratification. *Circulation*. 1996; 93:905–914. [PubMed: 8598081]
29. Carlin JB, Gurrin LC, Sterne JA, Morley R, Dwyer T. Regression models for twin studies: a critical review. *Int J Epidemiol*. 2005; 34:1089–1099. [PubMed: 16087687]
30. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. *Am J Med*. 1998; 105:32S–39S. [PubMed: 9707266]
31. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. *Circulation*. 1990; 81:491–497. [PubMed: 2105174]
32. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. *Circulation*. 1998; 97:716–720. [PubMed: 9498533]
33. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. *Circulation*. 2004; 109:III27–32. [PubMed: 15198963]

34. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation*. 2001; 104:2673–2678. [PubMed: 11723017]
35. Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. *Circulation*. 1997; 96:3390–3395. [PubMed: 9396432]
36. Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. *Atherosclerosis*. 1997; 129:111–118. [PubMed: 9069525]
37. Schroeder S, Enderle MD, Ossen R, Meisner C, Baumbach A, et al. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. *Am Heart J*. 1999; 138:731–739. [PubMed: 10502220]
38. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. *Am J Cardiol*. 1998; 82:1535–1539. A1537–1538. [PubMed: 9874063]
39. Pepine CJ. Silent myocardial ischemia: definition, magnitude, and scope of the problem. *Cardiol Clin*. 1986; 4:577–581. [PubMed: 3779718]
40. Deedwania PC, Carbajal EV. Silent myocardial ischemia. A clinical perspective. *Arch Intern Med*. 1991; 151:2373–2382. [PubMed: 1746993]
41. Laukkanen JA, Kurl S, Lakka TA, Tuomainen TP, Rauramaa R, et al. Exercise-induced silent myocardial ischemia and coronary morbidity and mortality in middle-aged men. *J Am Coll Cardiol*. 2001; 38:72–79. [PubMed: 11451298]
42. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF. Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease. *Eur Heart J*. 2005; 26:1402–1409. [PubMed: 15774494]
43. Fleg JL, Gerstenblith G, Zonderman AB, Becker LC, Weisfeldt ML, et al. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. *Circulation*. 1990; 81:428–436. [PubMed: 2297853]
44. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. *Circulation*. 1990; 81:748–756. [PubMed: 2306826]
45. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. *Diabetes Care*. 2004; 27:1954–1961. [PubMed: 15277423]
46. Rasulova N, Singh A, Demetriadou O, Georgiou G, Yiannakaras C, et al. Clinical significance of myocardial perfusion abnormalities in patients with varying degree of coronary artery stenosis. *Nucl Med Commun*. 2008; 29:129–136. [PubMed: 18094634]
47. Adamu U, Knollmann D, Almutairi B, Alrawashdeh W, Deserno V, et al. Stress/rest myocardial perfusion scintigraphy in patients without significant coronary artery disease. *J Nucl Cardiol*. 2010; 17:38–44. [PubMed: 19705212]
48. Karatzis EN, Ikonomidis I, Vamvakou GD, Papaioannou TG, Protogerou AD, et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. *Am J Cardiol*. 2006; 98:1424–1428. [PubMed: 17126643]
49. Kitta Y, Nakamura T, Kodama Y, Takano H, Umetani K, et al. Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis. *J Am Coll Cardiol*. 2005; 46:648–655. [PubMed: 16098430]

HIGHLIGHTS

- Silent ischemia is common and a prognostic factor for coronary artery disease (CAD)
- We examine twins free of symptomatic CAD using PET to diagnose subclinical ischemia
- Endothelial function was measured by flow-mediated dilation of brachial artery
- Endothelial dysfunction associated with a 2-fold increased risk of silent ischemia
- The association is independent and not confounded by genetic or familial factors

Table 1

Cardiovascular Risk Factors According to FMD Quartiles

Cardiovascular Risk Factors	FMD Quartiles				P-value for trend
	1 st (<2.7%)	2 nd (2.7-4.6%)	3 rd (4.6-7.0%)	4 th (>7%)	
N	110	97	107	102	
Age (mean± s.e)	55.6 ± 2.9	55.3 ± 3.16	55.5 ± 3.16	54.8 ± 3.6	0.12
Systolic BP, mm Hg (mean± s.e)	132.8 ± 14.4	133.6 ± 16.5	127.5 ± 15.1	127.7 ± 15.0	0.02
BMI, kg/m ² (mean± s.e)	29.4 ± 4.9	29.6 ± 4.5	29.4 ± 4.3	29.7 ± 5.8	0.71
Current Smoking (%)	29.0	22.0	27.0	22.0	0.34
Alcohol (no. drinks/week)	5.6 ± 9.6	6.6 ± 12.6	3.5 ± 5.2	3.5 ± 5.7	0.03
LDL Cholesterol, mg/dl (mean± s.e)	122.3 ± 32.7	131.0 ± 35.5	122.2 ± 31.2	119.8 ± 31.2	0.29
History of Hypertension (%)	23.6	25.0	26.4	25.0	0.78
History of Diabetes (%)	37.1	28.9	34.3	25.7	0.95
Taking Beta-blockers (%)	28.6	28.5	28.6	14.2	0.20
Taking Diuretics (%)	18.5	37.0	14.8	29.6	0.83
Taking Statins (%)	24.1	20.4	27.7	27.7	0.47
Taking ACE-inhibitors (%)	22.2	20.3	33.3	24.1	0.57
Taking Aspirin (%)	26.9	25.4	29.4	18.3	0.13

FMD=Flow Mediated Dilatation; BMI=Body Mass Index; LDL=Low Density Lipoprotei

Table 2

Myocardial Perfusion Imaging Data by FMD Quartile

Myocardial Perfusion Scores	FMD Quartiles				P-value for trend
	1 st (<2.7%)	2 nd (2.7-4.6%)	3 rd (4.6-7.0%)	4 th (>7%)	
N	110	97	107	102	
Summed Stress Score,	2.26 ± 5.2	2.12 ± 6.2	1.85 ± 3.6	1.22 ± 3.2	0.06
Summed Rest Score, mean	0.51 ± 2.1	0.62 ± 2.6	0.45 ± 2.0	0.45 ± 1.5	0.64
Summed Difference Score,	1.7 ± 4.9	1.5 ± 4.7	1.4 ± 2.8	0.7 ± 2.1	0.04
Abnormal Stress	39 (27)	41 (29)	36 (25)	24 (17)	0.007
Fixed Defects ² , N (%)	10 (24)	12 (27)	10 (24)	10 (24)	0.82
Reversible Defects ³ , N (%)	29 (28)	28 (26)	26 (25)	14 (14)	0.008

¹ Summed Stress Score 4

² Summed Rest Score 4

³ Summed Difference Score 4

Table 3

Unadjusted and Adjusted Odds Ratios for the Relationship between FMD Quartiles and Presence of Myocardial Perfusion Defects.

Myocardial Perfusion Defects	FMD Quartiles				p-value for trend
	1 st OR (95% CI)	2 nd OR (95% CI)	3 rd OR (95% CI)	4 th	
Reversible					
Unadjusted	2.0 (1.6, 2.7)	1.6 (1.2, 2.7)	1.4 (1.1, 2.7)	1.0	0.04
Adjusted *	1.9 (1.6, 2.6)	1.5(1.2, 2.1)	1.3 (1.1, 2.5)	1.0	0.03
Fixed Defects					
Unadjusted	1.5(0.7, 2.9)	1.1(0.4, 2.6)	1.3 (0.6, 3.1)	1.0	0.51
Ajusted *	1.5 (0.7, 1.1)	1.1 (0.4, 2.6)	1.3 (0.6, 3.1)	1.0	0.50

* Adjusted for age, smoking, body mass index (BMI), systolic blood pressure, plasma lipids, fasting plasma glucose